Straits Times Index
3,253.03 -9.51 (-0.29%) Nikkei
27,782.93 -100.85 (-0.36%) Hang Seng
20,226.64 +34.24 (+0.17%) FTSE 100
7,564.27 +80.02 (+1.07%) Bitcoin USD
28,631.55 +542.89 (+1.93%) CMC Crypto 200
620.89 +19.92 (+3.31%)
Precision BioSciences, Inc. (DTIL)
After hours:
- Business Wire
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
DURHAM, N.C., March 27, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023.
- Zacks
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
